Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005915 · ClinicalTrials.gov registry record
A Comparison of Two Anti-HIV Treatment Plans
A clinical trial of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 480
- Enrollment target
- 20
- Study locations
NCT00005915: Completed study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00005915 is a study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 480 participants, roughly in line with the 445-participant average among 542 other HIV Infections trials with a reported enrollment target. The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005915, a study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 480 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare 2 treatment plans to try to increase the effects of anti-HIV drugs in patients who are resistant to the drug effects. Sometimes the increase in a patient's viral load (the level of HIV in the blood) can be slowed or stopped by taking anti-HIV drugs. This does not always happen. Sometimes anti-HIV drugs work at first but then stop working. When most of the usual anti-HIV drugs no longer seem to work, the virus is called multidrug-resistant (MDR). This study will compare 2 treatment plans to try to increase the effects of anti-HIV drugs in patients with MDR virus.
Conditions Studied
Study Locations (20)
Texas
- Montrose Clinic - Houston
- Houston Veterans Administration Med Ctr - Houston
- Univ TX Health Science Ctr - Houston
California
- Community Consortium / UCSF - San Francisco
- Lawrence Goldyn, MD - San Francisco
Colorado
- Denver CPCRA / Denver Public Hlth - Denver
- Univ Hosp Infectious Disease - Denver
Louisiana
- Louisiana Comm AIDS Rsch Prog / Tulane Univ Med - New Orleans
- Our Lady of the Lake Regional Med Ctr - New Orleans
Michigan
- Wayne State Univ - WSU/DMC / Univ Hlth Ctr - Detroit
- Henry Ford Hosp - Detroit
New Jersey
- Southern New Jersey AIDS Clinical Trials - Camden
- North Jersey Community Research Initiative - Newark
New York
- Harlem AIDS Treatment Grp / Harlem Hosp Ctr - New York
- Bronx-Lebanon Hosp Ctr - The Bronx
Connecticut
- Yale U / New Haven Med Ctr / AIDS Clinical Trials Unit - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Est. Completion | 2004-06 |
What the finished NCT00005915 record still lists
NCT00005915 is an observational study that tracks outcomes without assigning an intervention. The registered 480 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 445-participant average among 542 other HIV Infections trials with a reported enrollment target.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 0 interventions.
NCT00005915 names 20 study sites across 12 states, led by Texas, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT00005915 about?
NCT00005915 is a clinical study titled "A Comparison of Two Anti-HIV Treatment Plans". The purpose of this study is to compare 2 treatment plans to try to increase the effects of anti-HIV drugs in patients who are resistant to the drug effects. Sometimes the increase in a patient's viral load (the level of HIV in the blood) can be slowed or stopped by taking anti-HIV drugs. This does...
What is the current status of trial NCT00005915?
This trial is currently completed. The enrollment target is 480 participants. Estimated completion is 2004-06.
What conditions does trial NCT00005915 study?
This clinical trial studies the following conditions: HIV Infections.
Who is sponsoring clinical trial NCT00005915?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005915 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, District of Columbia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00005915's enrollment target sits among peer trials
480 69th of 542 higher than 474 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01954992 · 480 participants · Phase 3
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
- NCT03023696 · 480 participants · NA
Can Prophylactic Foraminotomy Prevent C5 Palsy
- NCT04948060 · 480 participants · NA
Tribally Engaged Approaches to Lung Screening (TEALS)
- NCT05053230 · 480 participants · NA
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer